178 related articles for article (PubMed ID: 34298663)
1.
Carles M; Fechter T; Grosu AL; Sörensen A; Thomann B; Stoian RG; Wiedenmann N; Rühle A; Zamboglou C; Ruf J; Martí-Bonmatí L; Baltas D; Mix M; Nicolay NH
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298663
[TBL] [Abstract][Full Text] [Related]
2. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic
Thorwarth D; Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D
J Nucl Med; 2019 Dec; 60(12):1698-1704. PubMed ID: 31076504
[TBL] [Abstract][Full Text] [Related]
4. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
5. Textural features of hypoxia PET predict survival in head and neck cancer during chemoradiotherapy.
Sörensen A; Carles M; Bunea H; Majerus L; Stoykow C; Nicolay NH; Wiedenmann NE; Vaupel P; Meyer PT; Grosu AL; Mix M
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1056-1064. PubMed ID: 31773233
[TBL] [Abstract][Full Text] [Related]
6. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
7. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
[TBL] [Abstract][Full Text] [Related]
8. Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy.
Socarrás Fernández JA; Mönnich D; Leibfarth S; Welz S; Zwanenburg A; Leger S; Löck S; Pfannenberg C; La Fougère C; Reischl G; Baumann M; Zips D; Thorwarth D
Phys Imaging Radiat Oncol; 2020 Jul; 15():52-59. PubMed ID: 33043157
[TBL] [Abstract][Full Text] [Related]
9. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma.
Kikuchi M; Yamane T; Shinohara S; Fujiwara K; Hori SY; Tona Y; Yamazaki H; Naito Y; Senda M
Ann Nucl Med; 2011 Nov; 25(9):625-33. PubMed ID: 21720778
[TBL] [Abstract][Full Text] [Related]
10. The significance of partial volume effect on the estimation of hypoxic tumour volume with [
Kafkaletos A; Mix M; Sachpazidis I; Carles M; Rühle A; Ruf J; Grosu AL; Nicolay NH; Baltas D
EJNMMI Phys; 2024 May; 11(1):43. PubMed ID: 38722446
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
12. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
13. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
14. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
15. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
Rühle A; Wiedenmann N; Fennell JT; Mix M; Ruf J; Stoian R; Thomsen AR; Vaupel P; Baltas D; Grosu AL; Nicolay NH
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1650-1660. PubMed ID: 34773163
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
18. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the Prognostic Value of Radiomic Features in
Muzi M; Wolsztynski E; Fink JR; O'Sullivan JN; O'Sullivan F; Krohn KA; Mankoff DA
Tomography; 2020 Mar; 6(1):14-22. PubMed ID: 32280746
[TBL] [Abstract][Full Text] [Related]
20. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
